S&P 500   3,332.78 (-0.56%)
DOW   27,388.20 (-0.71%)
QQQ   276.05 (-0.41%)
AAPL   113.85 (-0.97%)
MSFT   208.08 (-0.65%)
FB   258.93 (+0.82%)
GOOGL   1,458.00 (-0.05%)
AMZN   3,161.56 (-0.39%)
TSLA   424.79 (+0.85%)
NVDA   526.72 (+1.02%)
BABA   277.14 (+0.41%)
CGC   14.57 (+2.53%)
MU   50.48 (+1.53%)
GE   6.08 (-1.94%)
AMD   81.33 (+2.33%)
T   28.18 (-0.70%)
F   6.57 (-1.79%)
ACB   4.84 (+1.26%)
GILD   62.07 (-1.24%)
NFLX   490.09 (-0.11%)
DIS   124.03 (-1.56%)
BA   163.24 (-1.71%)
BAC   23.63 (-1.91%)
S&P 500   3,332.78 (-0.56%)
DOW   27,388.20 (-0.71%)
QQQ   276.05 (-0.41%)
AAPL   113.85 (-0.97%)
MSFT   208.08 (-0.65%)
FB   258.93 (+0.82%)
GOOGL   1,458.00 (-0.05%)
AMZN   3,161.56 (-0.39%)
TSLA   424.79 (+0.85%)
NVDA   526.72 (+1.02%)
BABA   277.14 (+0.41%)
CGC   14.57 (+2.53%)
MU   50.48 (+1.53%)
GE   6.08 (-1.94%)
AMD   81.33 (+2.33%)
T   28.18 (-0.70%)
F   6.57 (-1.79%)
ACB   4.84 (+1.26%)
GILD   62.07 (-1.24%)
NFLX   490.09 (-0.11%)
DIS   124.03 (-1.56%)
BA   163.24 (-1.71%)
BAC   23.63 (-1.91%)
S&P 500   3,332.78 (-0.56%)
DOW   27,388.20 (-0.71%)
QQQ   276.05 (-0.41%)
AAPL   113.85 (-0.97%)
MSFT   208.08 (-0.65%)
FB   258.93 (+0.82%)
GOOGL   1,458.00 (-0.05%)
AMZN   3,161.56 (-0.39%)
TSLA   424.79 (+0.85%)
NVDA   526.72 (+1.02%)
BABA   277.14 (+0.41%)
CGC   14.57 (+2.53%)
MU   50.48 (+1.53%)
GE   6.08 (-1.94%)
AMD   81.33 (+2.33%)
T   28.18 (-0.70%)
F   6.57 (-1.79%)
ACB   4.84 (+1.26%)
GILD   62.07 (-1.24%)
NFLX   490.09 (-0.11%)
DIS   124.03 (-1.56%)
BA   163.24 (-1.71%)
BAC   23.63 (-1.91%)
S&P 500   3,332.78 (-0.56%)
DOW   27,388.20 (-0.71%)
QQQ   276.05 (-0.41%)
AAPL   113.85 (-0.97%)
MSFT   208.08 (-0.65%)
FB   258.93 (+0.82%)
GOOGL   1,458.00 (-0.05%)
AMZN   3,161.56 (-0.39%)
TSLA   424.79 (+0.85%)
NVDA   526.72 (+1.02%)
BABA   277.14 (+0.41%)
CGC   14.57 (+2.53%)
MU   50.48 (+1.53%)
GE   6.08 (-1.94%)
AMD   81.33 (+2.33%)
T   28.18 (-0.70%)
F   6.57 (-1.79%)
ACB   4.84 (+1.26%)
GILD   62.07 (-1.24%)
NFLX   490.09 (-0.11%)
DIS   124.03 (-1.56%)
BA   163.24 (-1.71%)
BAC   23.63 (-1.91%)
Log in
NASDAQ:NVUS

Novus Therapeutics News Headlines

$0.99
+0.03 (+3.44 %)
(As of 09/29/2020 12:21 PM ET)
Add
Compare
Today's Range
$0.97
Now: $0.99
$1.05
50-Day Range
$0.38
MA: $0.56
$1.11
52-Week Range
$0.25
Now: $0.99
$1.45
Volume20,906 shs
Average Volume1.72 million shs
Market Capitalization$19.27 million
P/E RatioN/A
Dividend YieldN/A
Beta3.12

Headlines

Novus Therapeutics (NASDAQ NVUS) News Headlines Today

Source:
DateHeadline
Short Interest in Novus Therapeutics Inc (NASDAQ:NVUS) Drops By 44.0%Short Interest in Novus Therapeutics Inc (NASDAQ:NVUS) Drops By 44.0%
americanbankingnews.com - September 28 at 6:22 AM
Novus Therapeutics Inc (NASDAQ:NVUS) Expected to Post Earnings of -$0.10 Per ShareNovus Therapeutics Inc (NASDAQ:NVUS) Expected to Post Earnings of -$0.10 Per Share
americanbankingnews.com - September 27 at 1:16 AM
Novus Therapeutics (NASDAQ:NVUS) Shares Up 9.2%Novus Therapeutics (NASDAQ:NVUS) Shares Up 9.2%
americanbankingnews.com - September 22 at 7:40 PM
Novus Therapeutics (NASDAQ:NVUS) Stock Price Down 13%Novus Therapeutics (NASDAQ:NVUS) Stock Price Down 13%
americanbankingnews.com - September 17 at 8:52 PM
Novus Therapeutics (NASDAQ:NVUS) Shares Gap Down to $1.11Novus Therapeutics (NASDAQ:NVUS) Shares Gap Down to $1.11
americanbankingnews.com - September 16 at 11:39 AM
Why Novus Therapeutics Is Trading Higher TodayWhy Novus Therapeutics Is Trading Higher Today
finance.yahoo.com - September 15 at 7:51 PM
Novus Therapeutics to Present at H.C. Wainwright and Cantor Global Investment ConferencesNovus Therapeutics to Present at H.C. Wainwright and Cantor Global Investment Conferences
finance.yahoo.com - September 15 at 7:51 PM
Novus Therapeutics rallies on Anelixis Therapeutics buyNovus Therapeutics rallies on Anelixis Therapeutics buy
seekingalpha.com - September 15 at 9:50 AM
Novus Therapeutics (NASDAQ:NVUS) Shares Gap Up to $0.38Novus Therapeutics (NASDAQ:NVUS) Shares Gap Up to $0.38
americanbankingnews.com - September 15 at 9:29 AM
The Week Ahead In Biotech: Viela FDA Decision, Hematology Conference Take Center StageThe Week Ahead In Biotech: Viela FDA Decision, Hematology Conference Take Center Stage
www.benzinga.com - June 7 at 1:55 PM
Why Novus Therapeutics Is Trading Lower TodayWhy Novus Therapeutics Is Trading Lower Today
www.benzinga.com - June 2 at 1:38 PM
Novus Therapeutics down big on failed ear infection studyNovus Therapeutics down big on failed ear infection study
seekingalpha.com - June 1 at 2:21 PM
Novus Therapeutics stock loses nearly half its value after disappointing drug trial resultsNovus Therapeutics stock loses nearly half its value after disappointing drug trial results
finance.yahoo.com - June 1 at 2:21 PM
Novus Therapeutics Announces Topline Results of Phase 2a Clinical Trial of OP0201 in Acute Otitis MediaNovus Therapeutics Announces Topline Results of Phase 2a Clinical Trial of OP0201 in Acute Otitis Media
finance.yahoo.com - June 1 at 9:21 AM
Hedge Funds Watching Novus Therapeutics, Inc. (NVUS) From AfarHedge Funds Watching Novus Therapeutics, Inc. (NVUS) From Afar
finance.yahoo.com - May 30 at 6:58 PM
Novus Therapeutics EPS misses by $0.31Novus Therapeutics EPS misses by $0.31
seekingalpha.com - May 15 at 9:49 AM
BRIEF-Novus Therapeutics Says Nasdaq Has Determined To Toll Compliance Period For Minimum Bid Price Requirement Through June 30 For CoBRIEF-Novus Therapeutics Says Nasdaq Has Determined To Toll Compliance Period For Minimum Bid Price Requirement Through June 30 For Co
www.reuters.com - April 25 at 2:22 AM
17 Healthcare Stocks Moving In Wednesdays Pre-Market Session17 Healthcare Stocks Moving In Wednesday's Pre-Market Session
www.msn.com - April 22 at 8:53 AM
Novus Therapeutics Inc.Novus Therapeutics Inc.
www.marketwatch.com - April 18 at 11:00 PM
We're A Little Worried About Novus Therapeutics's (NASDAQ:NVUS) Cash Burn RateWe're A Little Worried About Novus Therapeutics's (NASDAQ:NVUS) Cash Burn Rate
finance.yahoo.com - April 7 at 4:41 PM
6 Stocks Moving In Wednesdays After-Hours Session6 Stocks Moving In Wednesday's After-Hours Session
www.msn.com - March 26 at 10:38 PM
BRIEF-Novus Therapeutics Files For Resale Of 7.24 Mln Shares Of Common StockBRIEF-Novus Therapeutics Files For Resale Of 7.24 Mln Shares Of Common Stock
www.reuters.com - March 25 at 8:25 PM
Novus Therapeutics EPS misses by $0.06Novus Therapeutics EPS misses by $0.06
seekingalpha.com - March 17 at 9:20 AM
Novus Therapeutics Completes Enrollment of Phase 2a Trial of OP0201 in Pediatric Patients with Acute Otitis MediaNovus Therapeutics Completes Enrollment of Phase 2a Trial of OP0201 in Pediatric Patients with Acute Otitis Media
finance.yahoo.com - March 2 at 7:07 AM
Novus Therapeutics Provides Update on OP0201Novus Therapeutics Provides Update on OP0201
finance.yahoo.com - January 13 at 2:46 PM
Hedge Funds Have Never Been More Bullish On Novus Therapeutics, Inc. (NVUS)Hedge Funds Have Never Been More Bullish On Novus Therapeutics, Inc. (NVUS)
finance.yahoo.com - December 22 at 2:28 PM
Novus Therapeutics to Participate in Two Investor ConferencesNovus Therapeutics to Participate in Two Investor Conferences
finance.yahoo.com - November 29 at 1:36 PM
Novus Therapeutics EPS beats by $0.19Novus Therapeutics EPS beats by $0.19
seekingalpha.com - November 13 at 8:57 AM
Novus Therapeutics Reports Third Quarter 2019 Financial ResultsNovus Therapeutics Reports Third Quarter 2019 Financial Results
finance.yahoo.com - November 13 at 8:57 AM
Novus Therapeutics Receives FDA Guidance on OP0201 Phase 2a Study in Patients with Chronic Otitis Media with EffusionNovus Therapeutics Receives FDA Guidance on OP0201 Phase 2a Study in Patients with Chronic Otitis Media with Effusion
finance.yahoo.com - October 29 at 8:33 AM
Do Institutions Own Shares In Novus Therapeutics, Inc. (NASDAQ:NVUS)?Do Institutions Own Shares In Novus Therapeutics, Inc. (NASDAQ:NVUS)?
finance.yahoo.com - October 9 at 8:38 AM
Novus Therapeutics to Participate in Two Upcoming Investor ConferencesNovus Therapeutics to Participate in Two Upcoming Investor Conferences
finance.yahoo.com - August 29 at 11:03 AM
Novus Therapeutics Reports Second Quarter 2019 Financial ResultsNovus Therapeutics Reports Second Quarter 2019 Financial Results
finance.yahoo.com - August 13 at 6:48 PM
Adynxx Adds Gregory J. Flesher to Board of Directors, Completes Up-listing to OTCQB MarketAdynxx Adds Gregory J. Flesher to Board of Directors, Completes Up-listing to OTCQB Market
feeds.benzinga.com - July 22 at 7:42 AM
Investors Who Bought Novus Therapeutics (NASDAQ:NVUS) Shares A Year Ago Are Now Down 86%Investors Who Bought Novus Therapeutics (NASDAQ:NVUS) Shares A Year Ago Are Now Down 86%
finance.yahoo.com - July 11 at 5:18 PM
Novus Therapeutics to Present OP0201 Data at the 20th International Symposium on Recent Advances in Otitis MediaNovus Therapeutics to Present OP0201 Data at the 20th International Symposium on Recent Advances in Otitis Media
finance.yahoo.com - June 10 at 10:18 AM
Novus Therapeutics misses by $0.04Novus Therapeutics misses by $0.04
seekingalpha.com - May 14 at 7:05 PM
Novus Therapeutics Reports First Quarter 2019 Financial ResultsNovus Therapeutics Reports First Quarter 2019 Financial Results
finance.yahoo.com - May 14 at 7:05 PM
Tuesday 5/7 Insider Buying Report: NLY, NVUSTuesday 5/7 Insider Buying Report: NLY, NVUS
www.nasdaq.com - May 8 at 9:29 AM
Novus Therapeutics Announces Closing of $10.7 Million Registered Direct Offering Priced At-the-MarketNovus Therapeutics Announces Closing of $10.7 Million Registered Direct Offering Priced At-the-Market
finance.yahoo.com - May 2 at 6:36 PM
Equity offering pressures Novus, down 16%Equity offering pressures Novus, down 16%
seekingalpha.com - April 30 at 5:58 PM
Novus Therapeutics Announces $10.7 Million Registered Direct Offering Priced At-the-MarketNovus Therapeutics Announces $10.7 Million Registered Direct Offering Priced At-the-Market
finance.yahoo.com - April 30 at 9:25 AM
Novus down 28% on underwhelming results for lead candidate in middle ear infectionNovus down 28% on underwhelming results for lead candidate in middle ear infection
seekingalpha.com - April 22 at 5:20 PM
Novus Therapeutics Announces Results of Two Single-Dose OP0201 Phase 1 Clinical TrialsNovus Therapeutics Announces Results of Two Single-Dose OP0201 Phase 1 Clinical Trials
finance.yahoo.com - April 22 at 9:18 AM
Novus Therapeutics IncNovus Therapeutics Inc
www.bloomberg.com - March 19 at 9:50 AM
Novus Therapeutics Doses First Patients in Phase 2a Trial of OP0201 - Business WireNovus Therapeutics Doses First Patients in Phase 2a Trial of OP0201 - Business Wire
www.businesswire.com - February 20 at 9:48 AM
Novus Therapeutics to Participate in the 8th Annual SVB Leerink Global Healthcare ConferenceNovus Therapeutics to Participate in the 8th Annual SVB Leerink Global Healthcare Conference
finance.yahoo.com - February 20 at 9:48 AM
Novus Therapeutics Doses First Patients in Phase 2a Trial of OP0201Novus Therapeutics Doses First Patients in Phase 2a Trial of OP0201
finance.yahoo.com - February 19 at 9:55 AM
Company Profile for Novus Therapeutics, Inc.Company Profile for Novus Therapeutics, Inc.
finance.yahoo.com - February 16 at 9:31 AM
Novus Therapeutics Doses First Subjects in Phase 1 Pharmacodynamics Study of OP0201Novus Therapeutics Doses First Subjects in Phase 1 Pharmacodynamics Study of OP0201
finance.yahoo.com - February 11 at 10:56 AM
This page was last updated on 9/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.